Neelima Vidula

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 18

Top Topics

Radical Prostatectomy

Gene Expression

Prognostic Factors

Ejection Fraction

Top Venues

NPJ breast cancer

Journal of the American Heart Association

Breast cancer research and treatment

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Kelly E McCann, Shari B Goldfarb, Tiffany A Traina, Meredith M Regan, Neelima Vidula, Virginia G Kaklamani
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer. NPJ breast cancer 10 (1) (2024)
Yael Bar, Jennifer C Keenan, Andrzej Niemierko, Arielle J Medford, Steven Jay Isakoff, Leif W Ellisen, Aditya Bardia, Neelima Vidula
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer. NPJ breast cancer 10 (1) (2024)
Yael Bar, Jennifer C Keenan, Andrzej Niemierko, Arielle J Medford, Steven Jay Isakoff, Leif W Ellisen, Aditya Bardia, Neelima Vidula
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer. NPJ breast cancer 10 (1) (2024)
Yael Bar, Jennifer C Keenan, Andrzej Niemierko, Arielle J Medford, Steven Jay Isakoff, Leif W Ellisen, Aditya Bardia, Neelima Vidula
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer. NPJ breast cancer 10 (1) (2024)
Kelly E McCann, Shari B Goldfarb, Tiffany A Traina, Meredith M Regan, Neelima Vidula, Virginia G Kaklamani
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer. NPJ breast cancer 10 (1) (2024)
Yael Bar, Jennifer C Keenan, Andrzej Niemierko, Arielle J Medford, Steven Jay Isakoff, Leif W Ellisen, Aditya Bardia, Neelima Vidula
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer. NPJ breast cancer 10 (1) (2024)
Kelly E McCann, Shari B Goldfarb, Tiffany A Traina, Meredith M Regan, Neelima Vidula, Virginia G Kaklamani
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer. NPJ breast cancer 10 (1) (2024)
Saadia Sherazi, Susan Schleede, Scott McNitt, Carla Casulo, Jeremiah E Moore, Eugene Storozynsky, Arpan Patel, Neelima Vidula, Mehmet K Aktas, Clive S Zent, Llan Goldenberg
Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders. Journal of the American Heart Association 12 (6) (2023)
Saadia Sherazi, Susan Schleede, Scott McNitt, Carla Casulo, Jeremiah E Moore, Eugene Storozynsky, Arpan Patel, Neelima Vidula, Mehmet K Aktas, Clive S Zent, Llan Goldenberg
Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders. Journal of the American Heart Association 12 (6) (2023)
Neelima Vidula, Andrzej Niemierko, Katherine Hesler, Lianne Ryan, Beverly Moy, Steven Jay Isakoff, Leif W Ellisen, Dejan Juric, Aditya Bardia
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Neelima Vidula, Christina Yau, Hope S Rugo
Glutaminase (GLS1) gene expression in primary breast cancer. Breast cancer (Tokyo, Japan) (2023)
Saadia Sherazi, Susan Schleede, Scott McNitt, Carla Casulo, Jeremiah E Moore, Eugene Storozynsky, Arpan Patel, Neelima Vidula, Mehmet K Aktas, Clive S Zent, Llan Goldenberg
Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders. Journal of the American Heart Association (2023)
Neelima Vidula, Jeffrey M Peppercorn
Clicking Away to Capture Cancer Staging -The Benefits and Challenges of Completing Standardized Staging Modules. JCO oncology practice (2023)
Neelima Vidula, Andrew Lipman, Shumei Kato, Caroline Weipert, Katherine Hesler, Georges Azzi, Ahmed M Elkhanany, Dejan Juric, Estelamari Rodriguez, Colleen Faulkner, Paul Makhlouf, Kristin Price, Joyce O'Shaughnessy, Aditya Bardia
Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer. NPJ breast cancer 8 (1) (2022)
Neelima Vidula, Christina Yau, Hope Rugo
Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast cancer research and treatment 194 (3) (2022)
Neelima Vidula, Christina Yau, Hope S Rugo
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. Breast cancer research and treatment 187 (2) (2021)
Neelima Vidula, Sally Greenberg, Laura Petrillo, Jimmy Hwang, Michelle Melisko, Andrei Goga, Mark Moasser, Mark Jesus M Magbanua, John W Park, Hope S Rugo
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ breast cancer 7 (1) (2021)
Neelima Vidula, Christina Yau, Jiali Li, Laura J Esserman, Hope S Rugo
Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast cancer research and treatment 165 (1) (2017)